Keyphrases
Prostate Cancer
78%
Androgen Receptor
52%
Polyomavirus
36%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
32%
Tumor
29%
Neuroendocrine Prostate Cancer
29%
Small T Antigen
29%
Androgen Signaling
27%
Yes-associated Protein 1 (YAP1)
24%
Cell Survival
23%
Forkhead Box A1 (FOXA1)
22%
Enzalutamide
21%
Protein Phosphatase 2A (PP2A)
20%
In Cancer
19%
Castration-resistant Prostate Cancer
19%
Natural Killer Cells
19%
CREB5
19%
B7-H3
19%
FOSL1
19%
BRAF Alteration
19%
Androgen Deprivation Therapy
19%
Tumorigenesis
18%
Mouse Polyomavirus
17%
Prostate Cancer Patients
16%
Simian Virus 40 (SV40)
16%
Transcription Factor
14%
Tumor Biopsy
14%
Genome-scale
14%
Molecular Features
14%
Androgens
13%
Murine Double Minute 4 (MDM4)
13%
Cancer Patients
13%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
12%
Phosphoinositide 3-kinase (PI3K)
12%
Breast Cancer Patients
12%
Patient-derived Xenograft
12%
Kinase Signaling
11%
Immune Checkpoint Inhibitors
11%
Cancer Types
11%
Epithelial-to-mesenchymal Transition
11%
Vulnerability
11%
Prostate Tumor
11%
PARP Inhibitor (PARPi)
11%
Androgen Receptor Antagonist
11%
Therapeutic Target
11%
CD276
11%
Epigenomics
11%
RET Kinase
10%
Middle T Antigen
10%
Targeted Therapy
10%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
50%
Genomics
50%
Polyomavirus
40%
Phosphotransferase
36%
Kinase
36%
Signal Transduction
34%
Cancer Cell
31%
FOXA1
27%
Genetics
25%
Mitogen-Activated Protein Kinase
24%
Cell Survival
23%
Enzalutamide
22%
Simian Virus 40
22%
Immune Checkpoints
21%
MDM4
19%
Carcinogenesis
19%
FOSL1
19%
Blood Plasma
19%
Phosphoprotein Phosphatase
18%
Murine Polyomavirus
18%
Mesenchymal-Epithelial Transition
16%
Reprogramming
16%
Promoter Region
15%
YAP1
14%
Gene Expression
14%
Messenger RNA
14%
RNA
13%
Antigen Function
13%
P53
13%
Natural Killer Cell
13%
CD276
13%
Transcription Factors
12%
Wild Type
12%
Overall Survival
12%
Cell Cycle
12%
T Cell
11%
Exome
11%
RNA Sequencing
11%
Immunity
11%
Single-Nucleotide Polymorphism
10%
Isoform
9%
FLNB
9%
Cellular Differentiation
9%
HRAS
9%
BRCA2
9%
Surface-Enhanced Laser Desorption/Ionization
9%
Cancer Mortality
9%
Cell Infiltration
9%
Papillomaviridae
9%
Phosphoinositide 3-Kinase
9%
Medicine and Dentistry
Prostate Cancer
100%
Androgen Receptor
39%
Neoplasm
36%
Malignant Neoplasm
32%
Phosphotransferase
28%
Castration Resistant Prostate Cancer
25%
Enzalutamide
21%
Natural Killer Cell
19%
Signal Transduction
17%
Clustered Regularly Interspaced Short Palindromic Repeat
16%
Promoter Region
14%
Mitogen-Activated Protein Kinase
11%
Cancer Types
11%
Cancer Cell
10%
Androgen
10%
Disease
10%
DNA Damage Response
9%
Malignant Rhabdoid Tumour
9%
Bladder Tumor
9%
Patient with Non-Hodgkins Lymphoma
9%
Cell Function
9%
Nicotinamide
9%
Urogenital Tract Tumor
9%
Uterine Cancer
9%
Saracatinib
9%
Androgen Receptor Antagonist
9%
Protein Arginine Methyltransferase
9%
Prostate Tumor
9%
Vaccinia
9%
Actin
9%
Protein-Protein Interaction
9%
Cellular Infiltration
9%
Sarcomatoid
9%
Clear Cell Renal Cell Carcinoma
9%
Diagnosis
9%
Neurological System
9%
Immune Checkpoint Inhibitor
9%
Poly ADP Ribose Polymerase
9%
Transcription Factors
8%
Liquid Biopsy
7%
Protein P53
6%
DNA Methylation
6%
Targeted Therapy
5%
Gene Expression
5%
Cell Line
5%
Biopsy Technique
5%
Programmed Cell Death
5%
Cas9
5%
Enhancer Region
5%
